{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:02:00Z","timestamp":1762459320662},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13045-015-0221-6","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T14:03:17Z","timestamp":1445695397000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Complexity of FGFR signalling in metastatic urothelial cancer"],"prefix":"10.1186","volume":"8","author":[{"given":"Alejo","family":"Rodriguez-Vida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Saggese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Rudman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donal","family":"Landers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Kilgour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik-Tobias","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,24]]},"reference":[{"issue":"6","key":"221_CR1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.eururo.2013.03.032","volume":"63","author":"M Roupr\u00eat","year":"2013","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63(6):1059\u201371.","journal-title":"Eur Urol"},{"issue":"4","key":"221_CR2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","volume":"65","author":"JA Witjes","year":"2014","unstructured":"Witjes JA, Comp\u00e9rat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778\u201392.","journal-title":"Eur Urol"},{"issue":"4","key":"221_CR3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.urology.2010.04.020","volume":"76","author":"R Abouassaly","year":"2010","unstructured":"Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology. 2010;76(4):895\u2013901.","journal-title":"Urology"},{"issue":"7528","key":"221_CR4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558\u201362.","journal-title":"Nature"},{"key":"221_CR5","doi-asserted-by":"crossref","unstructured":"Bajorin DF, Plimack ER, Siefker-Radtke AO, Choueiri TK, De Wit R, Sonpavde G, et al. KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. J Clin Oncol 33, 2015 (suppl; abstr TPS4572).","DOI":"10.1200\/jco.2015.33.15_suppl.tps4572"},{"issue":"1","key":"221_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2014","unstructured":"Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2014;15(1):25\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"7492","key":"221_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"CGAR Network","year":"2014","unstructured":"Network CGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322.","journal-title":"Nature"},{"key":"221_CR8","unstructured":"cBioPortal for Cancer Genomics: http:\/\/www.cbioportal.org\/. Accessed 17 October 2015."},{"issue":"1","key":"221_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","volume":"213","author":"DC Tomlinson","year":"2007","unstructured":"Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213(1):91\u20138.","journal-title":"J Pathol"},{"issue":"9","key":"221_CR10","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","volume":"19","author":"L Xie","year":"2013","unstructured":"Xie L, Su X, Zhang L, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 2013;19(9):2572\u201383.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"221_CR11","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","volume":"2","author":"V Guagnano","year":"2012","unstructured":"Guagnano V, Kauffmann A, W\u00f6hrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118\u201333.","journal-title":"Cancer Discov"},{"key":"221_CR12","doi-asserted-by":"crossref","unstructured":"Andre F, Ranson M, Dean E, Varga A, Van der Noll R, Stockman PK, et al. Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2013: AACR; 2013. Abstract LB-145.","DOI":"10.1158\/1538-7445.AM2013-LB-145"},{"key":"221_CR13","doi-asserted-by":"crossref","unstructured":"Kilgour E, Ferry D, Saggese M, Arkenau HT, Rooney C, Smith NR, et al. Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. J Clin Oncol 32:5\u00a0s, 2014 (suppl; abstr 11010).","DOI":"10.1200\/jco.2014.32.15_suppl.11010"},{"key":"221_CR14","doi-asserted-by":"crossref","unstructured":"Arkenau HT, Saggese M, Hollebecque A, Mathewson A, Lemech CR, Landers D, et al. A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer. J Clin Oncol 32:5\u00a0s, 2014 (suppl; abstr 2620).","DOI":"10.1200\/jco.2014.32.15_suppl.2620"},{"key":"221_CR15","unstructured":"Paik PK, Shen R, Ferry D, Soria JC, Mathewson A, Kilgour E, et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data. J Clin Oncol 32:5s, 2014 (suppl; abstr 8035)."},{"key":"221_CR16","doi-asserted-by":"crossref","unstructured":"Bahleda R, Dienstmann R, Adamo B, Gazzah A, Infante JR, Zhong B, et al. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 32:5s, 2014 (suppl; abstr 2501).","DOI":"10.1200\/jco.2014.32.15_suppl.2501"},{"issue":"12","key":"221_CR17","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","volume":"20","author":"MW Wynes","year":"2014","unstructured":"Wynes MW, Hinz TK, Gao D, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014;20(12):3299\u2013309.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"221_CR18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-014-0070-8","volume":"7","author":"AD Smith","year":"2014","unstructured":"Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70.","journal-title":"J Hematol Oncol"},{"key":"221_CR19","doi-asserted-by":"crossref","unstructured":"Sequist LV, Cassier P, Varga A, Tabernero J, Schellens JH, Delord JP, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2014: AACR; 2014. Abstract CT326.","DOI":"10.1158\/1538-7445.AM2014-CT326"},{"issue":"5","key":"221_CR20","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085\u201394.","journal-title":"Cancer Res"},{"issue":"11","key":"221_CR21","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/modpathol.2012.102","volume":"25","author":"HU Schildhaus","year":"2012","unstructured":"Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012;25(11):1473\u201380.","journal-title":"Mod Pathol"},{"issue":"1","key":"221_CR22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","volume":"43","author":"K Freier","year":"2007","unstructured":"Freier K, Schwaenen C, Sticht C, et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2007;43(1):60\u20136.","journal-title":"Oral Oncol"},{"key":"221_CR23","doi-asserted-by":"crossref","unstructured":"von Loga K, Kohlhaussen J, Marx AH,\u00a0Sauter G, Grob T, Quaas A. FGFR1 amplification is linked to the squamous cell carcinoma subtype in esophageal carcinoma. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research(AACR), 6\u201310 April 2013. Washington DC. Abstr 3024.","DOI":"10.1158\/1538-7445.AM2013-3024"},{"issue":"5","key":"221_CR24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673\u201384.","journal-title":"Gut"},{"issue":"14","key":"221_CR25","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/onc.2009.489","volume":"29","author":"N Turner","year":"2010","unstructured":"Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013\u201323.","journal-title":"Oncogene"},{"issue":"16","key":"221_CR26","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-12-3950","volume":"73","author":"RG Liao","year":"2013","unstructured":"Liao RG, Jung J, Tchaicha J, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73(16):5195\u2013205.","journal-title":"Cancer Res"},{"issue":"25","key":"221_CR27","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","volume":"105","author":"A Dutt","year":"2008","unstructured":"Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105(25):8713\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"221_CR28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","volume":"119","author":"J Qing","year":"2009","unstructured":"Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest. 2009;119(5):1216\u201329.","journal-title":"J Clin Invest"},{"issue":"2","key":"221_CR29","first-page":"855","volume":"123","author":"BC Parker","year":"2013","unstructured":"Parker BC, Annala MJ, Cogdell DE, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest. 2013;123(2):855\u201365.","journal-title":"J Clin Invest"},{"key":"221_CR30","doi-asserted-by":"crossref","unstructured":"Bang YJ, Van Cutsem E, Mansoor W, Petty RD, Chao Y, Cunningham D, et al. A randomized, open-label phase II study of AZD4547 (AZD) versus paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with fibroblast growth factor receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. J Clin Oncol 33, 2015 (suppl; abstr 4014).","DOI":"10.1200\/jco.2015.33.15_suppl.4014"},{"key":"221_CR31","doi-asserted-by":"crossref","unstructured":"Smyth EC, Turner NC, Peckitt C, Pearson A, Brown G, Chua S, et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. J Clin Oncol 33, 2015 (suppl; abstr 2508).","DOI":"10.1200\/jco.2015.33.15_suppl.2508"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0221-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T22:07:22Z","timestamp":1567289242000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jhoonline.org\/content\/8\/1\/119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,24]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["221"],"URL":"https:\/\/doi.org\/10.1186\/s13045-015-0221-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,24]]},"article-number":"119"}}